Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3

NCT03937882 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

700

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndromes
Dry Eye

Interventions

DRUG: RGN-259
DRUG: Placebo

Sponsor

ReGenTree, LLC